Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
PremiumPress ReleasesAdverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
11d ago
Adverum Biotechnologies participates in a conference call with Truist
PremiumThe Fly
Adverum Biotechnologies participates in a conference call with Truist
23d ago
Adverum Biotechnologies initiated with an Outperform at Oppenheimer
PremiumThe Fly
Adverum Biotechnologies initiated with an Outperform at Oppenheimer
1M ago
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
PremiumPress ReleasesAdverum Biotechnologies to Participate in Upcoming May Investor Conferences
3M ago
Adverum Biotechnologies initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Adverum Biotechnologies initiated with a Buy at H.C. Wainwright
3M ago
Adverum Biotechnologies management to meet with Truist
PremiumThe Fly
Adverum Biotechnologies management to meet with Truist
3M ago
Adverum Biotechnologies trading halted, news pending
PremiumThe FlyAdverum Biotechnologies trading halted, news pending
4M ago
Brexit Uncertainty: Navigating New Risks and Regulatory Hurdles for Adverum Biotechnologies
PremiumCompany Announcements
Brexit Uncertainty: Navigating New Risks and Regulatory Hurdles for Adverum Biotechnologies
4M ago
Adverum Biotechnologies price target lowered to $2 from $3 at RBC Capital
PremiumThe Fly
Adverum Biotechnologies price target lowered to $2 from $3 at RBC Capital
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100